Leukemia Research
Research is a major component of the NH-Leukemia Program. We believe leukemia patients should have access to state-of-the-art and novel clinical research trials to ensure the best possible survival outcomes.
The Leukemia & Lymphoma Society (LLS) and the Dana-Farber Cancer Institute established a network of sites for clinical trial testing of innovative blood cancer therapies in community oncology settings across the country. This groundbreaking Blood Cancer Research Partnership (BCRP), dana-farber.org/BCRP, will bring clinical trials closer to where patients live and help to address one of the primary barriers to accessing new cancer therapies. The NH BMT, Leukemia, and Immunotherapy Program is one of ten sites selected to participate in this prestigious partnership. Please review Cooperative Groups.
Our experienced research team includes research nurses, pharmacists experienced in the handling of investigational agents, and laboratory personnel.
Treatment option(s) include standard of care treatment(s) or clinical research trials. Your physician will discuss the risks and benefits of all potential treatments, providing you with the information you need to make an informed decision. To help you and your family understand what is involved in a clinical trial, please click What is a Clinical Trial?
Important facts to know about clinical research:
The goal of clinical research trials is to determine the safety and efficacy of new drugs, which may improve survival and quality of life.
Participation in a clinical trial may offer you access to a new therapy for your disease, which is not otherwise available, or the use of an established treatment in a new setting.
Your participation in a clinical trial is voluntary.
When new clinical trial information is available, you will be informed by your leukemia physician.
Clinical Research Team